47 related articles for article (PubMed ID: 35807385)
1. Discovery of Glutamate Carboxypeptidase III Ligands to Compete the Uptake of [
Müller M; Lucaroni L; Favalli N; Bassi G; Neri D; Cazzamalli S; Oehler S
J Med Chem; 2024 May; 67(10):8247-8260. PubMed ID: 38716576
[TBL] [Abstract][Full Text] [Related]
2. Regulatory Considerations for Producing mRNA Vaccines for Clinical Trials.
Schmid A
Methods Mol Biol; 2024; 2786():321-337. PubMed ID: 38814402
[TBL] [Abstract][Full Text] [Related]
3. Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective.
Mattana F; Muraglia L; Barone A; Colandrea M; Saker Diffalah Y; Provera S; Cascio AS; Omodeo Salè E; Ceci F
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730595
[TBL] [Abstract][Full Text] [Related]
4. Quality Assurance Investigations and Impurity Characterization during Upscaling of [
Schmitl S; Raitanen J; Witoszynskyj S; Patronas EM; Nics L; Ozenil M; Weissenböck V; Mindt TL; Hacker M; Wadsak W; Brandt MR; Mitterhauser M
Molecules; 2023 Nov; 28(23):. PubMed ID: 38067427
[TBL] [Abstract][Full Text] [Related]
5. Innovation in Radionuclide Therapy for the Treatment of Prostate Cancers: Radiochemical Perspective and Recent Therapeutic Practices.
Deshayes E; Fersing C; Thibault C; Roumiguie M; Pourquier P; Houédé N
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370743
[TBL] [Abstract][Full Text] [Related]
6. Improved quality control of [
Kraihammer M; Garnuszek P; Bauman A; Maurin M; Alejandre Lafont M; Haubner R; von Guggenberg E; Gabriel M; Decristoforo C
EJNMMI Radiopharm Chem; 2023 Mar; 8(1):7. PubMed ID: 36971890
[TBL] [Abstract][Full Text] [Related]
7. Radiolysis-Associated Decrease in Radiochemical Purity of
Larenkov A; Mitrofanov I; Pavlenko E; Rakhimov M
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838872
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific membrane antigen theranostics: therapy with lutetium-177.
Ferdinandus J; Violet J; Sandhu S; Hofman MS
Curr Opin Urol; 2018 Mar; 28(2):197-204. PubMed ID: 29278583
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer - a review of patent literature.
Ha H; Kwon H; Lim T; Jang J; Park SK; Byun Y
Expert Opin Ther Pat; 2021 Jun; 31(6):525-547. PubMed ID: 33459068
[TBL] [Abstract][Full Text] [Related]
10. Production and Quality Control of [
Di Iorio V; Boschi S; Cuni C; Monti M; Severi S; Paganelli G; Masini C
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807385
[TBL] [Abstract][Full Text] [Related]
11. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A
J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Multidose Preparation of a Ready-to-Use
Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S
Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687
[No Abstract] [Full Text] [Related]
13. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer.
Escudero-Castellanos A; Ocampo-García B; Ferro-Flores G; Santos-Cuevas C; Morales-Ávila E; Luna-Gutiérrez M; Isaac-Olivé K
Nucl Med Commun; 2019 Mar; 40(3):278-286. PubMed ID: 30763290
[TBL] [Abstract][Full Text] [Related]
15. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
